WaveMan
WaveMan · Company
INSM · Insmed Inc
> Search tickers & screens ⌘K
LIVE
← All companies

INSM Insmed (INSM) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001104506
Quote by TradingView
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
367
13F, latest reported quarter
Conversions, 180 days
18
Codes C/M, not in net · $7.6M priced

What the filings say about INSM

Insiders, 180 days
-$59.8M net sold
7 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 1 sold
Latest: sale, 2026-06-10
Planned sales (Form 144), 90 days
$39.2M
4 notices

Insmed insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, INSMED Inc insiders sold a net $59.8M of stock across 531 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Brennan David R
Director
SELL
2026-09-11 SECtraded 2026-09-09
25,000
$3.1M
-25.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 1, 2021.
  • The trade is 63.7% of the 39,238 shares held after it.
  • 2 other insiders sold within 30 days.
  • 367 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Brennan David R sold about $3.1M of INSM on Sep 9, 2026; 2 other insiders sold within 30 days and 367 funds added in the latest 13F quarter.
SHAROKY MELVIN MD
Director
SELL
2026-08-19 SECtraded 2026-08-17
5,000
$637.6K
-25.4%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (4 buys, 4 sales), the last on Dec 5, 2025.
  • +20.4% median (+29.5% mean) 90-day return after 4 previous buys.
  • 4 other insiders sold within 30 days.
  • 367 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SHAROKY MELVIN MD sold about $637.6K of INSM on Aug 17, 2026; 4 other insiders sold within 30 days and 367 funds added in the latest 13F quarter.
Adsett Roger
Chief Operating Officer
SELL
2026-08-12 SECtraded 2026-08-10
239,850
$32.0M
-26.1%
Context
  • 44 earlier Form 4 trades (code P or S) here by this insider (44 sales), the last on Jun 3, 2026.
  • The trade is 242.9% of the 98,744 shares held after it.
  • 4 other insiders sold within 30 days.
  • 367 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Adsett Roger sold about $32.0M of INSM on Aug 10, 2026, the largest insider sale at the company on our record; 4 other insiders sold within 30 days and 367 funds added in the latest 13F quarter.
Flammer Martina M.D.
Chief Medical Officer
SELL
2026-08-07 SECtraded 2026-08-06
8,895
$1.1M
-30.7%
Context
  • 86 earlier Form 4 trades (code P or S) here by this insider (86 sales), the last on Jul 6, 2026.
  • The trade is 11.3% of the 78,764 shares held after it.
  • 3 other insiders sold within 30 days.
  • 367 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Flammer Martina M.D. sold about $1.1M of INSM on Aug 6, 2026; 3 other insiders sold within 30 days and 367 funds added in the latest 13F quarter.
Flammer Martina M.D.
Chief Medical Officer
SELL
2026-08-07 SECtraded 2026-08-06
18,278
$2.4M
-30.7%
Context
  • 86 earlier Form 4 trades (code P or S) here by this insider (86 sales), the last on Jul 6, 2026.
  • The trade is 30.2% of the 60,486 shares held after it.
  • 3 other insiders sold within 30 days.
  • 367 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Flammer Martina M.D. sold about $2.4M of INSM on Aug 6, 2026; 3 other insiders sold within 30 days and 367 funds added in the latest 13F quarter.
531 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 526 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$59.8M over 180 days
-$39.2M over 90 days
below 95% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
367 funds bought in last quarter
more than 96% of Pharma & Biotech
Revenue
+66.7% year over year
more than 82% of Pharma & Biotech
Margin
-210.5% net margin
below 66% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
6.4% of the float short (float per yahoo 2026-10-26) · 6.5 days to cover · settled 2026-09-30
more than 58% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch INSM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-41.7%12M
-43%-18%+7%+32%2025-102025-122026-022026-042026-062026-082026-10 2026-08-10 · Adsett Roger sold $32.0M2026-04-01 · Adsett Roger sold $10.3M2026-01-02 · Schaeffer Orlov S Nicole sold $6.0M2026-01-02 · Schaeffer Orlov S Nicole sold $5.4M2025-11-17 · LEE LEO sold $4.7M2025-12-05 · SHAROKY MELVIN MD sold $4.1M2025-11-12 · Schaeffer Orlov S Nicole sold $3.7M2025-11-17 · LEE LEO sold $3.4M2026-04-01 · Adsett Roger sold $3.1M2026-09-09 · Brennan David R sold $3.1M2025-11-17 · LEE LEO sold $3.0M2026-03-30 · Smith Michael Alexander sold $3.0M2025-11-17 · LEE LEO sold $2.9M2026-02-24 · Smith Michael Alexander sold $2.5M2026-08-06 · Flammer Martina M.D. sold $2.4M2025-11-11 · Flammer Martina M.D. sold $2.3M2026-01-02 · Schaeffer Orlov S Nicole sold $2.3M2025-11-11 · Flammer Martina M.D. sold $2.0M2025-11-14 · ANDERSON ELIZABETH M sold $2.0M2026-01-02 · Schaeffer Orlov S Nicole sold $1.6M2026-05-13 · Lewis William sold $1.5M2025-11-03 · Smith Michael Alexander sold $1.4M2026-04-06 · Lewis William sold $1.4M2025-11-12 · Schaeffer Orlov S Nicole sold $1.3M2026-05-18 · Lewis William sold $1.3M2026-06-25 · Lewis William sold $1.2M2026-05-14 · Flammer Martina M.D. sold $1.2M2025-12-01 · Flammer Martina M.D. sold $1.2M2026-05-11 · Flammer Martina M.D. sold $1.2M2026-01-12 · Lewis William sold $1.2M2026-01-12 · Lewis William sold $1.2M2026-08-06 · Flammer Martina M.D. sold $1.1M2026-04-01 · Adsett Roger sold $1.1M2026-02-09 · Lewis William sold $1.1M2025-11-11 · Flammer Martina M.D. sold $1.0M2025-11-24 · ANDERSON ELIZABETH M sold $1.0M2026-05-13 · Bonstein Sara sold $961.0K2026-01-20 · Lewis William sold $948.7K2025-12-04 · Lewis William sold $924.1K2026-05-18 · Lewis William sold $853.1K2026-01-06 · Flammer Martina M.D. sold $829.7K2026-07-06 · Flammer Martina M.D. sold $823.7K2026-09-10 · Brennan David R filed to sell $3.1M2026-08-17 · MELVIN SHAROKY filed to sell $637.6K2026-08-10 · Roger Adsett filed to sell $32.0M2026-08-06 · Martina Flammer filed to sell $3.5M2026-07-23 · William Lewis filed to sell $1.1M2026-07-09 · William Lewis filed to sell $1.3M2026-07-06 · Martina Flammer filed to sell $1.4M2026-06-25 · William Lewis filed to sell $2.2M2026-06-22 · Michael Smith filed to sell $173.0K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns INSM: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
16,143,583 sh
$1.7B
BlackRock, Inc.
15,807,984 sh
$1.7B
VANGUARD PORTFOLIO MANAGEMENT LLC
10,407,962 sh
$1.1B
JPMORGAN CHASE & CO
10,428,170 sh
$1.1B
VANGUARD CAPITAL MANAGEMENT LLC
9,790,865 sh
$1.0B

Congress trades in INSM

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Josh Gottheimer
Sold 2026-06-10 · disclosed 27 days later
$1,001 - $15,000
Gilbert Cisneros
Sold 2025-10-03 · disclosed 46 days later
$1,001 - $15,000
Gilbert Cisneros
Sold 2025-09-22 · disclosed 18 days later
$1,001 - $15,000
Gilbert Cisneros
Sold 2025-08-08 · disclosed 35 days later
$1,001 - $15,000
Gilbert Cisneros
Sold 2025-07-07 · disclosed 38 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

INSM planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Brennan David R
Filed 2026-09-10
$3.1M
MELVIN SHAROKY
Filed 2026-08-17
$637.6K
Roger Adsett
Filed 2026-08-10
$32.0M
Martina Flammer
Filed 2026-08-06
$3.5M
William Lewis
Filed 2026-07-23
$1.1M

INSM mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
VistaShares Target 15 DRUKMacro Distribution ETF
$1.3M position · as of 2026-07-31
7.5%
Fidelity Advisor Biotechnology Fund
$67.1M position · as of 2026-07-31
3.0%
VALUE LINE LARGER COMPANIES FOCUSED FUND, INC.
$11.7M position · as of 2026-06-30
2.7%
VanEck Biotech ETF
$10.6M position · as of 2026-06-30
2.7%
AlphaCentric Life Sciences and Healthcare Fund
$1.2M position · as of 2026-06-30
2.6%
Harbor Health Care ETF
$1.0M position · as of 2026-07-31
2.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
35 registered trials, 8 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
17
Phase 1
3 active
7
Phase 2
0 active
7
Phase 3
4 active
2
Not applicable
0 active
2
Multi-phase
1 active
What changed recently
A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healt
2026-09-26 · Not Yet Recruiting → Recruiting
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Mr. Lewis
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$14.5M
$127.9M
$4.5M
+423%
+20%
2024
$10.9M
$51.9M
$4.1M
+107%
-9%
2023
$10.4M
$17.7M
$4.2M
-7%
-8%
2022
$7.8M
$4.3M
$4.0M
-40%
-11%
2021
$7.3M
$2.8M
$3.3M
-18%
-1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $59.8M sold by insiders over 180 days, 367 funds added last quarter, $39.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

INSM financials

Revenue growth
+66.7%
XBRL, annual
Net margin
-210.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.1B
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-76.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$807.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
1.01x
long-term 2026-06-30 plus current 2024-06-30 (24 months older than the period end); equity 2026-06-30
Cash flow to debt
-1.01x
TTM operating cash flow over long-term 2026-06-30 plus current 2024-06-30 (24 months older than the period end)
Return on equity
-87.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-38.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-43.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$20.6B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2024-06-30 (24 months older than the period end), minus cash 2026-06-30
FCF yield
-4.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$606.4M$363.7M$305.2M$245.4M
Operating income-$1.2B-$878.3M-$709.6M-$457.3M
Net income-$1.3B-$913.8M-$749.6M-$481.5M
EPS (diluted)-6.42-5.57-5.34-3.91
Operating cash flow-$935.0M-$683.9M-$536.2M-$400.4M
Cash$510.4M$555.0M$482.4M$1.1B
Long-term debt$541.0M$1.1B$1.2B$1.1B
SEC XBRL, fiscal years, as known on 2026-10-28

INSM Stock Sonar score 6/7 axes

Find similar shapesCompare

INSM ranks highest on growth (82nd percentile) and profitability (49th), and lowest on insider conviction (2nd), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
49
Inputs
  • Return on equity-87.2% · 37 pct, sector of 545
  • Return on assets-38.2% · 54 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-43.9% · 56 pct, sector of 576
Financial health
35
Inputs
  • Debt to equity1.01x · 19 pct, sector of 352
  • Cash flow to debt-1.01x · 52 pct, sector of 371
Growth
82
Inputs
  • Revenue growth, YoY+66.7% · 82 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
2
Inputs
  • Net Form 4 buying (codes P and S), 180d-$59.8M · 4 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
39
Inputs
  • Funds adding, latest quarter367 · 96 pct, sector of 698
  • Congress net buyers, 365d-1 · 10 pct, sector of 49
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$60K · 12 pct, sector of 133
Risk and compliance
33
Inputs
  • Short interest, % of float+6.4% · 52 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+21.7% · 13 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

INSM filings, in plain words

Are Insmed insiders buying or selling INSM?

In the 180 days to 2026-10-28, Insmed insiders were net sellers, a net $59.8M across purchases and sales reported on Form 4, by 7 sellers.

Have members of Congress traded INSM?

Yes. In the year to 2026-10-28, 0 House members disclosed buying INSM and 1 House member disclosed selling it; the latest on record is a sale by Josh Gottheimer dated 2026-06-10.

Are there planned insider sales of INSM?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $39.2M of stock; the latest, by Brennan David R, was filed 2026-09-10.

Read the full summary

In the 180 days to 2026-10-28, Insmed insiders were net sellers of INSM, a net $59.8M across purchases and sales reported on Form 4 by 7 sellers. None of the 44 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 0 members of Congress disclosed buying INSM and 1 member disclosed selling it; the latest on record is a sale by Josh Gottheimer dated 2026-06-10. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $39.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies